RB binding protein 8, endonucleaseGenealiases: COM1 · CTIP · JAWAD · JWDS · RIM · SAE2
Q-omics provides the consensus-scored RBBP8 profile across patient tissues and cancer cell-line models. RBBP8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RBBP8 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RBBP8 RNA expression shows 19,917 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, HNSC, and UVM as cancer lineages where RBBP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP8 survival associations across molecular data types. RBBP8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP8 RNA expression–survival associations across cancer types. High RBBP8 expression shows unfavorable associations in ACC, MESO, HNSC and PAAD, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RBBP8 RNA expression.
This table summarizes RBBP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBBP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP8 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, STAD, LIHC and LUSC. The HNSC box plot shows higher RBBP8 RNA expression in tumor versus normal tissue (log2 FC = +1.376, t-test p < 0.001).
This table shows molecular features associated with RBBP8 in patient tissues and cancer cell lines. In patient samples, RBBP8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBBP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
